日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Exposure to Volatile Organic Compounds May Contribute to Atopic Dermatitis in Adults

接触挥发性有机化合物可能导致成人患特应性皮炎

期刊:Biomedicines
影响因子:3.9
doi:10.3390/biomedicines12071419
Tang, Kuo-Tung; Chen, Yu-Sin; Lee, Mey-Fann; Chen, Tzu-Ting; Lai, Chien-Chen; Lin, Chi-Chien; Chen, Yi-Hsing
发表日期：2024
文献求助 收藏

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

MEK抑制剂selumetinib联合pembrolizumab治疗晚期或转移性实体瘤的1期临床试验

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-024-01428-0
Chénard-Poirier, Maxime; Hansen, Aaron R; Gutierrez, Martin E; Rasco, Drew; Xing, Yan; Chen, Lin-Chi; Zhou, Heng; Webber, Andrea L; Freshwater, Tomoko; Sharma, Manish R
发表日期：2024
文献求助 收藏

A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors

一项针对晚期实体瘤患者的 ERK 抑制剂 MK-8353 联合帕博利珠单抗的 1b 期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-024-01461-z
Lakhani, Nehal J; Burris, Howard 3rd; Miller, Wilson H Jr; Huang, Mo; Chen, Lin-Chi; Siu, Lillian L
MAPK/ERK
发表日期：2024
文献求助 收藏

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

一项开放标签的 1b 期研究结果显示，ERK 抑制剂 MK-8353 联合 MEK 抑制剂 selumetinib 治疗晚期或转移性实体瘤患者。

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-022-01326-3
Stathis, Anastasios; Tolcher, Anthony W; Wang, Judy S; Renouf, Daniel J; Chen, Lin-Chi; Suttner, Leah H; Freshwater, Tomoko; Webber, Andrea L; Nayak, Tapan; Siu, Lillian L
MAPK/ERK
发表日期：2023
文献求助 收藏

Peptidylarginine Deiminase Type 2 Predicts Tumor Progression and Poor Prognosis in Patients with Curatively Resected Biliary Tract Cancer

肽酰精氨酸脱亚胺酶 2 型可预测胆道癌根治性切除患者的肿瘤进展和不良预后

期刊:Cancers
影响因子:
doi:10.3390/cancers15164131
Hon-Yi Lin, Chih-Chia Yu, Chen-Lin Chi, Chang-Kuo Wei, Wen-Yao Yin, Chih-En Tseng, Szu-Chin Li
肿瘤
发表日期：2023
文献求助 收藏

IRAK2, an IL1R/TLR Immune Mediator, Enhances Radiosensitivity via Modulating Caspase 8/3-Mediated Apoptosis in Oral Squamous Cell Carcinoma

IRAK2 是一种 IL1R/TLR 免疫介质，可通过调节 Caspase 8/3 介导的口腔鳞状细胞癌细胞凋亡来增强放射敏感性

期刊:Frontiers in Oncology
影响因子:3.5
doi:10.3389/fonc.2021.647175
Chih-Chia Yu, Michael W Y Chan, Hon-Yi Lin, Wen-Yen Chiou, Ru-Inn Lin, Chien-An Chen, Moon-Sing Lee, Chen-Lin Chi, Liang-Cheng Chen, Li-Wen Huang, Chia-Hui Chew, Feng-Chun Hsu, Hsuan-Ju Yang, Shih-Kai Hung
免疫
口腔癌
肿瘤细胞
Apoptosis
发表日期：2021
文献求助 收藏

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

口服MDM2拮抗剂idasanutlin每日和每周给药方案治疗晚期肿瘤患者的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-021-01141-2
Italiano, Antoine; Miller, Wilson H Jr; Blay, Jean-Yves; Gietema, Jourik A; Bang, Yung-Jue; Mileshkin, Linda R; Hirte, Hal W; Higgins, Brian; Blotner, Steven; Nichols, Gwen L; Chen, Lin Chi; Petry, Claire; Yang, Qi Joy; Schmitt, Christophe; Jamois, Candice; Siu, Lillian L
MDM2
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

A qualitative study of clinical narrative competence of medical personnel

一项关于医务人员临床叙事能力的定性研究

期刊:BMC Medical Education
影响因子:3.2
doi:10.1186/s12909-020-02336-6
Chu, Shao-Yin; Wen, Chin-Chen; Lin, Chi-Wei
发表日期：2020
文献求助 收藏

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

MDM2拮抗剂RO6839921治疗急性髓系白血病患者的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-020-00907-4
Uy, Geoffrey L; Assouline, Sarit; Young, Anne-Marie; Blotner, Steven; Higgins, Brian; Chen, Lin-Chi; Yee, Karen
白血病
MDM2
发表日期：2020
文献求助 收藏

Selection of aptamers for AMACR detection from DNA libraries with different primers

利用不同引物从DNA文库中筛选用于AMACR检测的适体

期刊:RSC Advances
影响因子:4.6
doi:10.1039/c8ra01808a
Yang, Deng-Kai; Chou, Chia-Fu; Chen, Lin-Chi
发表日期：2018
文献求助 收藏